09 September 2019 Written by CN1699 Services Article viewed 8 times (2 times in the last week)

SoniVie, a company based in Israel, won FDA Breakthrough Device Designation for its TIVUS intravascular ultrasound system for patients suffering from pulmonary arterial hypertension (PAH). 

The TIVUS system is designed to help improve pulmonary vascular resistance by ablating diseased nerves related to PAH, yet sparing vessels walls and other nearby tissues. It works thanks to a special catheter, delivered into the pulmonary artery via a right heart cath procedure, that emits ultrasound at frequencies that destroy nerve cells.


For more information, visit:

SoniVie

Grace T

Managing Editor - CN1699 Services